Emmanuel Nony

This inventor holds 29 USPTO granted patents and 5 published patent applications, plus 4 CIPO patents and 13 EPO patents, primarily in Immunotherapy Biomarkers. Top assignees: Laboratoire Francais Du Fractionnement Et Des Biotechnologies, Stallergenes, Lfb Biotechnologies. Active years: 2009-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Emmanuel Nony. Retrieved from https://idiyas.com/inventor/emmanuel-nony

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 29 (Patent Applications = 5)

% Patents Active = 48.3

CIPO Patents = 4 (Patent Applications = 1)

EPO Patents = 13 (Patent Applications = 18)

Average Co-Inventor Count = 5.5

ph-index = 5

Forward Citations = 120(Granted Patents)

Company Filing History:

16 out of 97

Laboratoire Francais Du Fractionnement Et Des Biotechnologies

National Institute of Health and Medical Research

patents

where one patent can have more than one assignee

Years Active: 2009-2021

Loading Chart...

Areas of Expertise:

Immune Response

Biomarkers

Monoclonal Antibodies

ADCC Optimization

Immunotherapy Efficacy

Dendritic Cells

Recombinant Proteins

Inflammatory Diseases

Cancer Treatment

Glycosylation Sites

Allergen Diagnostics

Effector Cells

29 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11015221 - Markers of immune response (2021-05-25),

2. 10884002 - Sialylated fetuin-A as a marker of immunotherapy efficacy (2021-01-05),

3. 10364425 - Recombinant or transgenic factor VII composition, each factor VII molecule having two N-glycosylation sites with defined glycan units (2019-07-30),

4. 10344272 - Recombinant or transgenic factor VII composition, each factor VII molecule having two N-glycosylation sites with defined glycan units (2019-07-09),

5. 10190166 - Methods for identifying dendritic cell subsets, for determining if a patient is developing a regulatory or an effector immune response, and for determining response to immunotherapy (2019-01-29),

6. 10101341 - Biomarkers of immunotherapy efficacy (2018-10-16),

7. 10081683 - Monoclonal antibodies with enhanced ADCC function (2018-09-25),

8. 9879089 - Use of ADCC-optimized antibodies for treating low-responder patients (2018-01-30),

9. 9868770 - Recombinant Der P 2 expressed in Pichia Pastoris as a 'natural-like' allergen for immunotherapy and diagnostic purposes (2018-01-16),

10. 9822185 - Use of IGG1 immunoglobulins and/or ligands of the CD32 receptor for treating inflammatory diseases and incidents via the mucosa (2017-11-21),

11. 9718890 - Monoclonal antibodies with enhanced ADCC function (2017-08-01),

12. 9718889 - Monoclonal antibodies with enhanced ADCC function (2017-08-01),

13. 9708409 - Monoclonal antibodies with enhanced ADCC function (2017-07-18),

14. 9187568 - [object Object] (2015-11-17),

15. 9109020 - Use of ADCC-optimized antibodies for treating weak patients (2015-08-18),

Title: Inventor Emmanuel Nony

Introduction: Emmanuel Nony is a renowned inventor based in Antony, France, known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Emmanuel Nony holds several patents in various technological domains, showcasing his continuous commitment to pushing the boundaries of innovation.

Career Highlights: With a career spanning over two decades, Emmanuel Nony has established himself as a visionary inventor, with a keen focus on developing solutions that have a tangible impact on society.

Collaborations: Throughout his career, Emmanuel Nony has collaborated with leading tech companies, research institutions, and universities to further his inventions and bring them to market, solidifying his reputation as a forward-thinker in the industry.

Conclusion: Emmanuel Nony's passion for innovation and his relentless drive to create have cemented his status as a prominent figure in the world of inventors, with his work continuing to inspire future generations of innovators.

Profile summary based on public USPTO records.